Chronic Inflammation as an Overlooked Link between Cardiovascular and Kidney Disease: A Focus on IL-6 and C-Reactive...

Area of Science:

• Cardiology
• Nephrology
• Immunology

Background:

• Chronic subclinical inflammation is a key factor in the progression of chronic kidney disease (CKD) and cardiovascular disease (CVD).
• Inflammation and oxidative stress create a detrimental cycle contributing to cardiorenal syndrome, worsening outcomes and mortality.
• Biomarkers such as Interleukin-6 and C-reactive protein (CRP) indicate disease severity and prognosis in CKD and CVD patients.

Purpose of the Study:

• To review the established role of chronic inflammation in CKD and CVD.
• To explore the potential of targeting inflammation to reduce residual risk in cardiorenal syndrome.
• To discuss the implications of inflammatory biomarkers for clinical assessment and novel therapeutic strategies.

Main Methods:

• Literature review of studies investigating inflammation in CKD and CVD.
• Analysis of the role of inflammatory biomarkers, specifically CRP and hsCRP.
• Examination of current treatment limitations and potential for anti-inflammatory interventions.

Main Results:

• Inflammation is a significant driver of kidney and cardiovascular damage, linked to increased mortality.
• High-sensitivity C-reactive protein (hsCRP) serves as a prognostic marker for residual inflammatory risk.
• Current therapies do not fully address the impact of inflammation on disease progression.

Conclusions:

• Clinicians should consider assessing chronic inflammation in CKD patients, particularly those with CVD, using markers like hsCRP.
• Inflammatory risk presents a promising target for developing novel therapeutic approaches.
• Anti-inflammatory strategies may be crucial for reducing residual risk in patients with cardiorenal syndrome.